MYC and neoplasm: Recently, spliceosome mutation-relevant splicing abnormality, MYC-driven splicing burden, and MCL1 oncogene addiction have been proposed to confer preferential tumor cell inhibition for SF3b-targeting splicing modulators9,14,15.